Arndt Vogel, MD, Hannover Medical School, Hannover, Germany, discusses findings in the elderly patient cohort of the Phase III RATIONALE-301 trial (NCT03412773), which assessed first-line tislelizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Patients who are over 65 years old were defined as elderly in the study, and they were found have a lower disease state. Overall survival was higher in the elderly cohort compared to the overall population, and no new safety signals were observed. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.